AstraZeneca (LON:AZN) has earned a consensus rating of “Hold” from the twenty-four brokerages that are covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, six have given a hold recommendation, thirteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is GBX 5,184.40 ($71.63).
A number of equities analysts have recently commented on the stock. Credit Suisse Group reaffirmed an “outperform” rating and set a GBX 5,800 ($80.13) target price on shares of AstraZeneca in a research report on Tuesday, February 20th. Goldman Sachs set a GBX 3,800 ($52.50) target price on shares of AstraZeneca and gave the stock a “sell” rating in a research report on Monday, February 19th. UBS reaffirmed a “neutral” rating on shares of AstraZeneca in a research report on Monday, January 15th. Citigroup reaffirmed a “buy” rating and set a GBX 6,200 ($85.66) target price on shares of AstraZeneca in a research report on Thursday, March 1st. Finally, Barclays reissued a “top pick” rating on shares of AstraZeneca in a report on Friday, March 9th.
LON AZN remained flat at $GBX 4,895.50 ($67.64) during trading on Wednesday. AstraZeneca has a 52-week low of GBX 4,260 ($58.86) and a 52-week high of GBX 5,520 ($76.26).
The firm also recently announced a dividend, which was paid on Monday, March 19th. Investors of record on Thursday, February 15th were given a dividend of GBX 133.60 ($1.85) per share. The ex-dividend date was Thursday, February 15th. This is an increase from AstraZeneca’s previous dividend of $68.90. This represents a yield of 2.8%.
In other AstraZeneca news, insider Philip A. J. Broadley bought 415 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The stock was bought at an average cost of GBX 4,846 ($66.95) per share, for a total transaction of £20,110.90 ($27,785.16).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.